Profile data is unavailable for this security.
About the company
American Oncology Network, Inc. is an alliance of physicians and seasoned healthcare leaders. The Company has offered a progressive model of physician-led, community-based oncology management. Its business is focused on caring for adult and senior populations with medical oncology and related care needs, including members of Medicare Advantage (MA) plan run by private insurance companies on behalf of the Centers for Medicare and Medicaid Services, or CMS, as well as traditional Fee-For-Service (FFS) Medicare, Medicaid, other government healthcare programs and commercial insurance populations. It provides patients with a variety of services, including in-house professional and technical pathology providing complete pathology reports; in-house specialty pharmacy with patient education, financial assistance and 24/7 patient assistance, and care management support services including nutrition guidance. The Company's network represents more than 220 providers practicing across 20 states.
- Revenue in USD (TTM)1.28bn
- Net income in USD-9.12m
- Incorporated2020
- Employees1.53k
- LocationAmerican Oncology Network Inc14543 Global Pkwy #110FORT MYERS 33913United StatesUSA
- Phone+1 (360) 949-1111
- Fax+1 (302) 655-5049
- Websitehttps://www.aoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prenetics Global Ltd | 21.74m | -54.35m | 70.91m | 800.00 | -- | 0.3433 | -- | 3.26 | -4.60 | -5.31 | 1.94 | 16.91 | 0.0768 | 3.37 | 0.9505 | -- | -19.92 | -- | -24.55 | -- | 40.61 | -- | -259.40 | -- | 2.29 | -5.92 | 0.0112 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| CRYO-CELL International, Inc. | 31.37m | -9.73m | 72.94m | 82.00 | -- | -- | -- | 2.33 | -1.18 | -1.18 | 3.77 | -1.25 | 0.4908 | 10.31 | 4.74 | 382,579.60 | -15.23 | 0.4686 | -21.73 | 0.7099 | 72.79 | 70.09 | -31.02 | 0.8133 | 0.449 | 5.93 | -- | -- | 3.32 | 1.41 | -443.57 | -- | 60.30 | -- |
| Burning Rock Biotech Ltd (ADR) | 74.40m | -90.50m | 85.15m | 786.00 | -- | 0.8011 | -- | 1.14 | -88.38 | -88.38 | 72.66 | 10.36 | 0.4091 | 1.75 | 3.57 | 94,658.96 | -49.76 | -37.09 | -66.95 | -45.29 | 67.59 | 70.02 | -121.63 | -123.88 | 3.09 | -- | 0.00 | -- | -4.58 | 20.81 | 32.69 | -- | -17.61 | -- |
| ProPhase Labs Inc | 28.72m | -23.60m | 95.97m | 113.00 | -- | 2.02 | -- | 3.34 | -1.34 | -1.34 | 1.64 | 2.49 | 0.3098 | 5.81 | 0.7872 | 254,115.00 | -25.45 | 0.9106 | -33.00 | 1.12 | 18.41 | 50.32 | -82.18 | 0.9325 | 1.73 | -20.42 | 0.1953 | 665.78 | -63.81 | 27.59 | -190.90 | -- | 86.46 | -- |
| American Oncology Network Inc | 1.28bn | -9.12m | 110.68m | 1.53k | -- | -- | -- | 0.0865 | -1.19 | -1.19 | 145.02 | -10.16 | -- | -- | -- | 838,809.80 | -- | -- | -- | -- | 6.47 | -- | -4.92 | -- | 1.38 | -3.52 | 0.5499 | -- | 11.27 | -- | -- | -- | -- | -- |
| DLH Holdings Corp | 402.59m | 3.07m | 149.87m | 3.20k | 53.44 | 1.40 | 7.42 | 0.3723 | 0.197 | 0.197 | 27.68 | 7.50 | 1.17 | -- | 6.57 | 125,807.80 | 0.8924 | 5.38 | 1.11 | 7.20 | 20.92 | 20.56 | 0.7631 | 3.41 | -- | 1.50 | 0.6069 | 0.00 | -4.88 | 23.05 | -93.73 | -28.16 | -0.903 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lumyna Investments Ltd.as of 30 Sep 2022 | 112.12k | 1.06% |
| Applied Capital LLCas of 31 Mar 2024 | 37.50k | 0.35% |
| Geode Capital Management LLCas of 31 Mar 2024 | 22.69k | 0.21% |
| BIP Wealth LLCas of 31 Mar 2024 | 17.79k | 0.17% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 10.54k | 0.10% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 5.66k | 0.05% |
| UBS Securities LLCas of 31 Mar 2024 | 3.35k | 0.03% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.43k | 0.01% |
| Center for Financial Planning, Inc. (Michigan)as of 31 Mar 2024 | 334.00 | 0.00% |
| Tower Research Capital LLCas of 31 Mar 2024 | 307.00 | 0.00% |
